Navigation Links
New Biologics Must Show Improvements in Efficacy, Safety and Cost-Benefit Compared with Currently Available Agents for Inclusion on Formularies in Argentina, Brazil and Mexico
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that novel biologics must demonstrate improvements in efficacy, safety and cost-benefit compared with currently listed agents for a given disease to be included on both national and institutional formularies in Argentina, Brazil and Mexico. According to the new Strategic Insights report entitled Trends in Reimbursement of Biologics Across the Growth Markets: Focus on Argentina, Brazil and Mexico, numerous novel biological agents are in late-stage development for a range of oncology indications, rheumatoid arthritis and diabetes, and could reach these markets in the next two to three years.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO)

The report notes that the market for biologics is lucrative, and growth in this sector will outpace the overall oncology and rheumatoid arthritis drug markets, resulting in an increase share of biologics in these markets.

"While approval from the regulatory bodies of Argentina, Brazil and Mexico may be reached shortly after a drug's approval in the major pharmaceutical markets, it may precede inclusion on formularies in these markets by several years," said Decision Resources Group Analyst Natalia Reoutova, M.A., M.Sc. "Historically, authorization was sufficient for market access terms but today, it's only one step toward favorable market access."

About Strategic Insights
Strategic Insights is a new series of high-level, strategic reports from Decision Resources Group thought leaders, designed for corporate executives in the biopharma industry. The Strategic Insights series evaluates global industry trends that are shaping the healthcare market, and delivers targeted, actionable insight in an easy-to-read PowerPoint format.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
2. Synthetic Biologics Announces Proposed Public Offering of Common Stock
3. Synthetic Biologics SYN-004 for the Prevention of C. difficile Infections Named a "Top Project to Watch" by Elsevier Business Intelligence
4. Synthetic Biologics Reports Third Quarter 2013 Financial Results and Operational Update
5. Synthetic Biologics to Report Third Quarter 2013 Financial Results
6. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
7. Samsung BioLogics unterzeichnet strategische Herstellungspartnerschaft mit Roche
8. Biosimilars Need Same Names as Original Biologics, Hospira Says at World Health Organization (WHO) Meeting
9. Samsung BioLogics Signs a Strategic Manufacturing Partnership with Roche
10. Gallus Strengthens Biologics CMO Business with Acquisition of Laureate
11. Synthetic Biologics Responds to Recent CDC Report on Threat of "Super Bugs"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers ... Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including ... issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and global ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the ... paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue ... Bik joined uBiome in October 2016 from her previous position at Stanford University ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 Shareholder ... an investigation into whether the board members of CoLucid ... fiduciary duties in connection with the proposed sale of ... a biopharmaceutical company that develops small molecules for the ... 2017, CoLucid announced it had signed a definitive merger ...
(Date:1/18/2017)... IRVING, Texas , Jan. 18, 2017 /PRNewswire/ ... science, and the Lustgarten Foundation, the largest private ... support a clinical trial evaluating the impact of ... is providing clinical trial enrollment services to identify ... and facilitate communication between treating physicians and study ...
Breaking Biology Technology:
(Date:1/12/2017)... PUNE, India , January 12, 2017 A ... 2015 - 2022," projects that the global biometric technology market is expected to generate ... to 2022. Continue Reading ... ...      (Logo: ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):